Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Typ

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. ABBV
4. META
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Typ

Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company

February 28, 2019 6:51 AM EST

RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining a Outperform rating.

"We believe this quarter is marking the emergence of SRPT as a full-fledged gene therapy company and leader in neuro GT drug... More

Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen

February 28, 2019 6:21 AM EST

Cowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.

Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More

Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust

February 27, 2019 11:55 AM EST

SunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary results from a Phase I/IIa MYO-101 study in Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) or beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss,... More